Biotech investor Claus Christiansen believes drugs to treat fibrosis will represent a huge market in the near future. His company Nordic Biosciences has discovered a biomarker that can predict the spread of lung fibrosis.
BY LONNI LYNGE
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.